7.2101  -1.09 (-13.13%)		01-30 15:51
Open: 8.42 High: 8.42 Volume: 54,279		Pre. Close: 8.3 Low: 7 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	13.73	1-year :	17.16
Resists	First :	11.75	Second :	14.69
Pivot price	10.02
Supports	First :	7	Second :	5.82
MAs	MA(5) :	8.72	MA(20) :	10.96
	MA(100) :	12.1	MA(250) :	9.95
MACD	MACD :	-1.5	Signal :	-1.2
%K %D	K(14,3) :	3.9	D(3) :	4.9
RSI	RSI(14): 24.5
52-week	High :	41.79	Low :	5.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ QNRX ] has closed below the lower bollinger band by 6.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 39% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	9.13 - 9.21	9.21 - 9.26
Low:	8.07 - 8.15	8.15 - 8.2
Close:	8.2 - 8.32	8.32 - 8.4

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Fri, 30 Jan 2026
This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - simplywall.st

Tue, 27 Jan 2026
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - Yahoo Finance

Tue, 20 Jan 2026
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome - Intellectia AI

Tue, 20 Jan 2026
Saudi move could bring first-ever Netherton treatment to patients in 2026 - Stock Titan

Tue, 20 Jan 2026
Quoin Pharmaceuticals Files Breakthrough Medicine - GlobeNewswire

Tue, 11 Nov 2025
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	14 (M)
Held by Insiders	6.8 (%)
Held by Institutions	51.1 (%)
Shares Short	30 (K)
Shares Short P.Month	71 (K)

EPS	-29.18
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-2.07
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-99.5 %
Return on Equity (ttm)	-651.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-16.79
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-0.25
PEG Ratio	0
Price to Book value	-3.48
Price to Sales	0
Price to Cash Flow	-0.57

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.